-1753895386100.webp&w=3840&q=75)
2025 NOSCM | Novel Advances in T-Cell NHL Therapies
Overview
Dr. Francine Foss discussed new T-cell NHL therapies, highlighting EBV-related disease classification and CD30+ frontline Brentuximab use. Promising combos include duvelisib with romidepsin or azacytidine. EZH2 and JAK inhibitors showed subtype-specific efficacy. Bispecifics had mixed results; trials continue.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Francine Foss, MD
Date of Release
July 30th, 2025
-1753895653633.webp&w=3840&q=75)
-1753895561853.webp&w=3840&q=75)